Nephrocare Healt

Why is Nephrocare Health Services Ltd falling/rising?

As of 30-Aug, Nephrocare Health Services Ltd's stock price is rising to 691.80, reflecting a 1.15% increase. This upward trend is supported by strong financial performance, including a net profit growth of 15.34% and positive cash flow, despite a decline in investor participation.

As of 30-Aug, Nephrocare Health Services Ltd's stock price is rising, currently at 691.80, reflecting a change of 7.85 (1.15%) upwards. This increase can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after two consecutive days of decline, which indicates a potential recovery in investor sentiment. Additionally, the stock has outperformed its sector by 0.8% today, suggesting that it is gaining traction compared to its peers.<BR><BR>The stock also reached an intraday high of Rs 702.15, marking a 2.66% increase, which further demonstrates positive momentum. Furthermore, Nephrocare Health Services Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend in the short to medium term.<BR><BR>On a fundamental level, the company is net-debt free, which is a positive indicator for investors. It has reported a significant growth in net profit of 15.34% and has declared positive results for the last two consecutive quarters. The operating cash flow is at its highest, and net sales have grown by 25.28% over the last nine months, contributing to a favorable outlook for the company.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 36.38% against the 5-day average. Additionally, institutional investors have reduced their stake by 0.75% in the previous quarter, which could indicate some caution among larger investors. Despite these factors, the overall positive performance metrics and recent price movements suggest that the stock is currently on an upward trajectory.

Which are the latest news on Nephrocare Healt?

Should I buy, sell or hold Nephrocare Health Services Ltd?

What does Nephrocare Healt do?

Nephrocare Health Services Ltd, a small-cap healthcare company founded in 2009, reported net sales of 282 Cr and a net profit of 32 Cr for June 2026, with a market cap of INR 6,826 Cr. Key financial metrics include a P/E ratio of 80.00 and a return on equity of 6.88%.

Overview: <BR>Nephrocare Health Services Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History: <BR>Nephrocare Health Services Ltd was incorporated in 2009 as "Nephrocare Health Services Private Limited" in Hyderabad. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 282 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 32 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 6,826 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 80.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 6.88% <BR>Price to Book: 6.12 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Nephrocare Healt?

Nephrocare Healt's peers include Vijaya Diagnostics, Indegene, Metropolis Health, Thyrocare Tech, Suven Life Sciences, Vimta Labs, Krsnaa Diagnostics, Tarsons Products, and Suraksha Diagnostics. Most peers show below-average growth and management risk, with Suraksha Diagnostics having the highest 1-year return at 1.98%.

Peers: The peers of Nephrocare Healt are Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Tarsons Products, and Suraksha Diagno.<BR><BR>Quality Snapshot: Excellent management risk is observed at Vijaya Diagnost., Thyrocare Tech., and Suraksha Diagno., while Average management risk is found at Indegene, Metropolis Healt, Vimta Labs, and Krsnaa Diagnost., and the rest. Below Average management risk is noted for Suven Life Scie. and Tarsons Products. All peers exhibit Below Average growth except for Suraksha Diagno. which has Good growth, while the rest show Below Average growth. Excellent capital structure is present in Vijaya Diagnost., Indegene, Thyrocare Tech., Vimta Labs, and Krsnaa Diagnost., while Average capital structure is found at Tarsons Products, and Below Average capital structure is noted for Suven Life Scie.<BR><BR>Return Snapshot: Suraksha Diagno. has the highest 1-year return at 1.98%, while Krsnaa Diagnost. has the lowest at -30.98%, with Nephrocare Healt's 1-year return being N/A. Additionally, Krsnaa Diagnost. and Tarsons Products have negative six-month returns.

How big is Nephrocare Healt?

As of 14th August, Nephrocare Health Services Ltd has a market capitalization of 7,008.96 Cr, with recent Net Sales of 1,052.82 Cr and a Net Profit of 85.11 Cr.

As of 14th August, Nephrocare Health Services Ltd has a market capitalization of 7,008.96 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Nephrocare reported Net Sales of 1,052.82 Cr and a Net Profit of 85.11 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 1,116.49 Cr and Total Assets of 1,436.90 Cr.

Are Nephrocare Health Services Ltd latest results good or bad?

Nephrocare Health Services Ltd's latest results show strong revenue and net profit growth, with a 51.02% increase in net profit to ₹30.37 crores and a 34.65% rise in revenue to ₹265.62 crores. However, the decline in operating margins to 20.25% raises concerns about profitability sustainability, suggesting a mixed outlook for investors.

Nephrocare Health Services Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹30.37 crores for Q4 FY26, which is a significant increase of 51.02% year-on-year. Additionally, revenue grew by 34.65% year-on-year, reaching ₹265.62 crores, indicating strong demand and successful execution of its expansion strategy.<BR><BR>However, there are concerns regarding profitability metrics. The operating margin decreased to 20.25%, down from 23.43% in the previous quarter, reflecting increased operational costs associated with expansion and inflationary pressures. This margin compression raises questions about the sustainability of profitability moving forward.<BR><BR>Overall, while the revenue and net profit growth are commendable, the decline in operating margins suggests that the company is facing challenges that need to be monitored closely. Investors may view the results as good in terms of growth but should be cautious about the implications of the margin compression.